ClinicalTrials.gg
CompletedNCT05934292Updated Sep 30, 2026Results posted

Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Renal Impairment Study (MK-0616-020)

A Phase 1 interventional study of Enlicitide Decanoate in Hypercholesterolaemia, sponsored by Merck Sharp & Dohme LLC. Completed at 5 sites in United States. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Updated Sep 30, 2026Posted results revised1 site added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
33
Allocation
Non-randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Hypercholesterolemia by Merck & Co., Inc — 1 open to participants now, 3 under way, 3 of them phase 3. Hypercholesterolemia · Merck & Co., Inc.

Enrollment
24th of 27
33 · median 500
Started
2023
with 3 others
Phase 1
6 of 29
none open now
Registered
21st of 29
by date

Among the 29 studies in Hypercholesterolemia by Merck & Co., Inc, this one is the 24th largest by enrollment of the 27 interventional ones that give a count, is one of 4 that started in 2023, is one of 6 in phase 1, and was the 21st registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 29 studies in Hypercholesterolemia by Merck & Co., Inc is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Hypercholesterolemia by Merck & Co., Inc, or all of them as a file.
02

Study summary

The primary objective of the study is to compare the plasma pharmacokinetics (PK) of enlicitide decanoate following a single 20 mg dose in participants on a background of statin therapy with varying degrees of renal impairment (moderate, severe, end stage renal disease [ESRD]) to those of healthy mean matched control participants on a background of statin therapy. There is no formal hypothesis.

Read the detailed description

Panel C included participants with ESRD. No urine samples could be obtained on Panel C participants and hence no pharmacokinetic (PK) analysis could be performed for Panel C participants as pre-specified in the protocol.

03

Conditions studied

  • Hypercholesterolaemia
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be in good health with the exception of renal impairment (RI) and hypercholesterolemia for participants in Panels A, B, and C. Participants with RI that have stable, chronic medical or psychiatric conditions, including but not limited to hypertension, hypercholesterolemia, diabetes mellitus, hyper- or hypothyroidism, gout, and chronic anxiety or depression may be included at the discretion of the investigator
  • (BMI) ≥ 18 kg/m\^2 and ≤ 40 kg/m\^2, inclusive
  • Be on a stable dose of any statin therapy defined as: no changes to dose or type of statin therapy for at least 2 months prior to Screening and participant anticipates no changes to statin therapy throughout the study until the poststudy visit

Exclusion criteria

Exclusion Criteria:

  • History or presence of renal artery stenosis
  • Had a functioning renal transplant in the past 5 years and is taking transplant medication
  • Participants in panels A, B and D: Has rapidly fluctuating renal function as determined by historical measurements
  • Has a history gastrointestinal disease which might affect food and drug absorption, as determined by the investigator, or has had gastric bypass or similar surgery
  • History of cancer ()
  • History of significant multiple and/or severe allergies, or has had an anaphylactic reaction or significant intolerability to prescription or nonprescription drugs or food
  • Has received an anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) small molecule treatment, monoclonal antibody, or short interfering RNA (siRNA) or RNA interference (ie, Inclisiran) within 12 months prior to Screening
  • Participants with RI (Panels A, B, and C): Taking medications to treat chronic medical conditions and/or conditions associated with renal disease, if participant has not been on a stable regimen for at least 1 month (other than statins, which require a stable dose for at least 2 months) prior to administration of the initial dose of study intervention, and/or is unable to withhold the use of the medication(s) within 4 hours prior to and 4 hours after administration of study intervention
  • Participated in another study within 4 weeks prior to the prestudy (screening) visit
  • Consumes greater than 3 servings of alcoholic beverages per day
  • Consumes excessive amounts, defined as greater than 6 servings of caffeinated beverages per day
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Panel A: Moderate Renal Impairment (RI)

    Participants receive Enlicitide Decanoate 20 mg tablet single dose orally on Day 1

    Drug: Enlicitide Decanoate

  • Experimental
    Panel B: Severe RI

    Participants receive Enlicitide Decanoate 20 mg tablet single dose orally on Day 1

    Drug: Enlicitide Decanoate

  • Experimental
    Panel C: End-Stage Renal Disease (ESRD) on Hemodialysis (HD)

    Participants receive Enlicitide Decanoate 20 mg tablet orally on Day 1 and Day 16.

    Drug: Enlicitide Decanoate

  • Experimental
    Panel D: Healthy Controls

    Participants receive Enlicitide Decanoate 20 mg tablet single dose orally on Day 1.

    Drug: Enlicitide Decanoate

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-Inf) of Enlicitide Decanoate

    AUC0-inf was a measure of the total amount of drug in the plasma from the dose administration extrapolated to infinity. Blood for plasma samples was collected at pre-specified timepoints to determine the AUC0-inf of enlicitide decanoate for Panel A, B, C, and D participants. Per protocol, Panel C ESRD on HD arm was separated into two arms: Panel C ESRD - enlicitide decanoate pre-hemodialysis and Panel C ESRD - enlicitide decanoate post-hemodialysis to report AUC0-inf. Per protocol, mean AUC0-inf was reported.

    Time frame: Predose and 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 120, 168, and 240 hours postdose

  2. AUC From Time 0 to Last Measurable Concentration (AUClast) of Enlicitide Decanoate

    AUClast was defined as the area under the concentration-time curve of enlicitide decanoate from time zero to last measurable concentration. Blood for plasma samples was collected at pre-specified timepoints to determine the AUClast of enlicitide decanoate in Panel A, B, C, and D participants. Per protocol, Panel C ESRD on HD arm was separated into two arms: Panel C ESRD - enlicitide decanoate pre-hemodialysis and Panel C ESRD - enlicitide decanoate post-hemodialysis to report AUClast. Per protocol, mean AUClast was reported.

    Time frame: Predose and 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 120, 168, and 240 hours postdose

  3. Maximum Plasma Concentration (Cmax) of Enlicitide Decanoate

    Cmax was defined as the maximum or peak concentration of enlicitide decanoate observed after its administration. Blood for plasma samples was collected at pre-specified time points to determine the Cmax of enlicitide decanoate in Panel A, B, C and D participants. Per protocol, Panel C ESRD on HD arm was separated into two arms: Panel C enlicitide decanoate pre-hemodialysis and Panel C enlicitide decanoate post-hemodialysis to report Cmax. Per protocol, mean Cmax was reported.

    Time frame: Predose and 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 120, 168, and 240 hours postdose

  4. Time to Maximum Plasma Concentration (Tmax) of Enlicitide Decanoate

    Tmax was defined as the time required for a study drug to reach maximum concentration in plasma. Blood for plasma samples was collected at pre-specified time points to determine the Tmax of enlicitide decanoate in Panel A, B, C and D participants. Per protocol, Panel C ESRD on HD arm was separated into two arms: Panel C enlicitide decanoate pre-hemodialysis and Panel C enlicitide decanoate post-hemodialysis to report Tmax. Per protocol, mean Tmax was reported.

    Time frame: Predose and 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 120, 168, and 240 hours postdose

  5. Apparent Terminal Half-life (t1/2) of Enlicitide Decanoate

    Half-life (t1/2) was defined as the time required for plasma drug concentration of enclitide decanoate to decrease by 50% from peak. Blood for plasma samples was collected at pre-specified time points to determine the t1/2 of enlicitide decanoate in Panel A, B, C and D participants. Per protocol, Panel C ESRD on HD arm was separated into two arms: Panel C enlicitide decanoate pre-hemodialysis and Panel C enlicitide decanoate post-hemodialysis to report t1/2. Per protocol, mean t1/2 was reported.

    Time frame: Predose and 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 120, 168, and 240 hours postdose

  6. Apparent Clearance (CL/F) of Enlicitide Decanoate

    CL/F was the apparent total clearance of enlicitide decanoate in plasma over time. Blood for plasma samples was collected at pre-specified timepoints to determine the CL/F of enlicitide decanoate for Panel A, B, C, and D participants. Per protocol, Panel C ESRD on HD arm was separated into two arms: Panel C enlicitide decanoate pre-hemodialysis and Panel C enlicitide decanoate post-hemodialysis to report CL/F. Per protocol, mean CL/F was reported.

    Time frame: Predose and 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 120, 168, and 240 hours postdose

  7. Apparent Volume of Distribution (Vz/F) of Enlicitide Decanoate

    Vz/F was the apparent volume of distribution of enlicitide decanoate between the plasma and the rest of the body, after dose, assessed as the total volume of enlicitide decanoate that would need to be uniformly distributed to achieve the desired plasma drug concentration. Blood for plasma samples was collected at pre-specified time points to determine the Vz/F of Enlicitide Decanoate in Panel A, B, C, and D participants. Per protocol, Panel C ESRD on HD arm was separated into two arms: Panel C enlicitide decanoate pre-hemodialysis and Panel C enlicitide decanoate post-hemodialysis to report Vz/F. Per protocol, mean Vz/F was reported.

    Time frame: Predose and 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 120, 168, and 240 hours postdose

Secondary outcomes

  1. Panel C: Dialysate Clearance (CLd) of Enlicitide Decanoate

    CLd was the measure of the amount of enlicitide decanoate cleared from plasma via dialysis. Per protocol, Panel C ESRD on HD arm was separated into two arms: Panel C enlicitide decanoate pre-hemodialysis and Panel C enlicitide decanoate post-hemodialysis. Urine samples were to be collected for Panel C participants to determine mean CLd.

    Time frame: Predose and 0, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, and 48 hours postdose

  2. Panel C: Dialysate Concentration (Cd) of Enlicitide Decanoate

    Cd was the measure of the concentration of enlicitide decanoate in dialysate. Per protocol, Panel C ESRD on HD arm was separated into two arms: Panel C enlicitide decanoate pre-hemodialysis and Panel C enlicitide decanoate post-hemodialysis. Urine samples were to be collected for Panel C participants to determine mean Cd.

    Time frame: Predose and 0, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, and 48 hours postdose

  3. Panel C: Amount of Enlicitide Decanoate Excreted (AEd) in Dialysate

    AEd was the measure of the amount of enlicitide decanoate excreted in the dialysate. Per protocol, Panel C ESRD on HD arm was separated into two arms: Panel C enlicitide decanoate pre-hemodialysis and Panel C enlicitide decanoate post-hemodialysis. Urine samples were to be collected for Panel C participants to determine mean AEd.

    Time frame: Predose and 0, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, and 48 hours postdose

  4. Panel C: Percentage of Dose (%Dose) of Enlicitide Decanoate Excreted in Dialysate

    %Dose was the percentage of the dose of enlicitide decanoate excreted in the dialysate. Per protocol, Panel C ESRD on HD arm was separated into two arms: Panel C enlicitide decanoate pre-hemodialysis and Panel C enlicitide decanoate post-hemodialysis. Urine samples were to be collected for Panel C participants to determine %Dose.

    Time frame: Predose and 0, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, and 48 hours postdose

  5. Amount of Enlicitide Decanoate Excreted in Urine From 0 to 24 Hours (AE0-24) After Administration of Enlicitide Decanoate

    AE0-24 was the measure of the amount of enlicitide decanoate excreted at 0 to 24 hours. Urine samples were to be collected to determine the AE0-24 after administration of enlicitide decanoate for Panels A, B, C, and D. Per protocol, Panel C ESRD on HD arm was separated into two arms: Panel C enlicitide decanoate pre-hemodialysis and Panel C enlicitide decanoate post-hemodialysis to report AE0-24. Per protocol, mean AE0-24 was reported.

    Time frame: Predose and 0, 0.5, 1, 1.5, 2, 4, 8, 12, and 24 hours postdose

  6. Percentage of Unchanged Enlicitide Decanoate Excreted in Urine (Fe)

    Fe was the measure of the percentage of unchanged enlicitide decanoate excreted in the urine. The percentage of enlicitide decanoate that was excreted unchanged in urine over the 24-hr collection interval (Fe) was calculated as 100 times the ratio of Ae0-24 and dose. Urine samples were to be collected to determine the Fe after administration of enlicitide decanoate for Panels A, B, C, and D. Per protocol, Panel C ESRD on HD arm was separated into two arms: Panel C enlicitide decanoate pre-hemodialysis and Panel C enlicitide decanoate post-hemodialysis to report Fe.

    Time frame: Predose and 0, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, and 48 hours postdose

  7. Renal Clearance (CLr) of Enlicitide Decanoate

    CLr was the measure of how quickly enlicitide decanoate was removed from the plasma by the kidney and excreted in urine. Urine samples were to be collected to determine the CLr after administration of enlicitide decanoate for Panels A, B, C, and D. Per protocol, Panel C ESRD on HD arm was separated into two arms: Panel C enlicitide decanoate pre-hemodialysis and Panel C enlicitide decanoate post-hemodialysis to report CLr. Per protocol, mean CLr was reported.

    Time frame: Predose and 0, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, and 48 hours postdose

  8. Number of Participants Who Experienced an Adverse Event (AE)

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who experienced an AE were reported.

    Time frame: Up to approximately 30 days

  9. Panels A, B, and D: Number of Participants Who Discontinued From the Study Due to an AE

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of Panel A, B, and D participants who discontinued study treatment due to an AE were reported.

    Time frame: Up to approximately 30 days

  10. Panel C: Number of Participants Who Discontinued From the Study Treatment Due to an AE

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of Panel C participants who discontinued study treatment due to an AE were reported.

    Time frame: Up to approximately 30 days

07

Results

Posted Feb 17, 2025

Participant flow

Participant flow — Overall Study
MilestonePanel A: Moderate Renal Impairment (RI)Panel B: Severe RIPanel C: End-Stage Renal Disease (ESRD) on Hemodialysis (HD)Panel D: Healthy Controls
Started8898
Completed8888
Not completed0010
Withdrew: Lost to follow-up0010

Outcome measures

PrimaryArea Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-Inf) of Enlicitide Decanoate

AUC0-inf was a measure of the total amount of drug in the plasma from the dose administration extrapolated to infinity. Blood for plasma samples was collected at pre-specified timepoints to determine the AUC0-inf of enlicitide decanoate for Panel A, B, C, and D participants. Per protocol, Panel C ESRD on HD arm was separated into two arms: Panel C ESRD - enlicitide decanoate pre-hemodialysis and Panel C ESRD - enlicitide decanoate post-hemodialysis to report AUC0-inf. Per protocol, mean AUC0-inf was reported.

Time frame:
Predose and 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 120, 168, and 240 hours postdose
Reported as:
Geometric mean · hr*nmol/Liter
Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-Inf) of Enlicitide Decanoate
hr*nmol/LiterPanel A: Moderate Renal Impairment (RI)Panel B: Severe RIPanel C: ESRD - Enlicitide Decanoate Pre-HemodialysisPanel C: ESRD - Enlicitide Decanoate Post-HemodialysisPanel D: Healthy Controls
Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-Inf) of Enlicitide Decanoate733 (499 to 1080)554 (379 to 809)850 (538 to 1350)570 (404 to 804)487 (316 to 752)
Statistical analysis
  • Panel A: Moderate Renal Impairment (RI) vs Panel D: Healthy Controls · Geometric mean ratio: 1.50 · 90% CI 0.98 to 2.31Geometric mean ratio (GMR) and 90% confidence interval (CI) were calculated using a linear fixed effects model performed on natural log-transformed values. GMR: Panel A-Moderate Renal Impairment (RI)/Panel D-Healthy controls
  • Panel B: Severe RI vs Panel D: Healthy Controls · Geometric Mean Ratio · Geometric mean ratio: 1.14 · 90% CI 0.74 to 1.74GMR and 90% confidence interval (CI) were calculated using a linear fixed effects model performed on natural log-transformed values. GMR: Panel B-Severe RI/Panel D-Healthy controls
  • Panel C: ESRD - Enlicitide Decanoate Pre-Hemodialysis vs Panel D: Healthy Controls · Geometric mean ratio: 1.17 · 90% CI 1.10 to 2.78GMR and 90% CI were calculated using a linear fixed effects model performed on natural log-transformed values. GMR: Panel C-ESRD Enlicitide Decanoate Pre-Hemodialysis/ Panel D-Healthy Controls
  • Panel C: ESRD - Enlicitide Decanoate Post-Hemodialysis vs Panel D: Healthy Controls · Geometric mean ratio: 1.75 · 90% CI 0.77 to 1.77GMR and 90% CI were calculated using a linear fixed effects model performed on natural log-transformed values. GMR: Panel C-ESRD Enlicitide Decanoate Post-Hemodialysis/ Panel D-Healthy Controls
PrimaryAUC From Time 0 to Last Measurable Concentration (AUClast) of Enlicitide Decanoate

AUClast was defined as the area under the concentration-time curve of enlicitide decanoate from time zero to last measurable concentration. Blood for plasma samples was collected at pre-specified timepoints to determine the AUClast of enlicitide decanoate in Panel A, B, C, and D participants. Per protocol, Panel C ESRD on HD arm was separated into two arms: Panel C ESRD - enlicitide decanoate pre-hemodialysis and Panel C ESRD - enlicitide decanoate post-hemodialysis to report AUClast. Per protocol, mean AUClast was reported.

Time frame:
Predose and 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 120, 168, and 240 hours postdose
Reported as:
Geometric mean · hr*nmol/Liter
AUC From Time 0 to Last Measurable Concentration (AUClast) of Enlicitide Decanoate
hr*nmol/LiterPanel A: Moderate Renal Impairment (RI)Panel B: Severe RIPanel C: ESRD - Enlicitide Decanoate Pre-HemodialysisPanel C: ESRD - Enlicitide Decanoate Post-HemodialysisPanel D: Healthy Controls
AUC From Time 0 to Last Measurable Concentration (AUClast) of Enlicitide Decanoate735 (506 to 1070)362 (145 to 904)649 (343 to 1230)538 (376 to 769)456 (297 to 701)
Statistical analysis
  • Panel A: Moderate Renal Impairment (RI) vs Panel D: Healthy Controls · Geometric mean ratio: 1.61 · 90% CI 1.05 to 2.46GMR and 90% confidence interval (CI) were calculated using a linear fixed effects model performed on natural log-transformed values. GMR: Panel A-Moderate Renal Impairment (RI)/Panel D-Healthy controls
  • Panel B: Severe RI vs Panel D: Healthy Controls · Geometric mean ratio: 0.79 · 90% CI 0.37 to 1.72GMR and 90% confidence interval (CI) were calculated using a linear fixed effects model performed on natural log-transformed values. GMR: Panel B-Severe RI/Panel D-Healthy controls
  • Panel C: ESRD - Enlicitide Decanoate Pre-Hemodialysis vs Panel D: Healthy Controls · Geometric mean ratio: 1.42 · 90% CI 0.80 to 2.54GMR and 90% CI were calculated using a linear fixed effects model performed on natural log-transformed values. GMR: Panel C-ESRD Enlicitide Decanoate Pre-Hemodialysis/ Panel D-Healthy Controls
  • Panel C: ESRD - Enlicitide Decanoate Post-Hemodialysis vs Panel D: Healthy Controls · Geometric mean ratio: 1.18 · 90% CI 0.78 to 1.78GMR and 90% CI were calculated using a linear fixed effects model performed on natural log-transformed values. GMR: Panel C-ESRD Enlicitide Decanoate Post-Hemodialysis/ Panel D-Healthy Controls
PrimaryMaximum Plasma Concentration (Cmax) of Enlicitide Decanoate

Cmax was defined as the maximum or peak concentration of enlicitide decanoate observed after its administration. Blood for plasma samples was collected at pre-specified time points to determine the Cmax of enlicitide decanoate in Panel A, B, C and D participants. Per protocol, Panel C ESRD on HD arm was separated into two arms: Panel C enlicitide decanoate pre-hemodialysis and Panel C enlicitide decanoate post-hemodialysis to report Cmax. Per protocol, mean Cmax was reported.

Time frame:
Predose and 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 120, 168, and 240 hours postdose
Reported as:
Geometric mean · nmol/Liter
Maximum Plasma Concentration (Cmax) of Enlicitide Decanoate
nmol/LiterPanel A: Moderate Renal Impairment (RI)Panel B: Severe RIPanel C: ESRD - Enlicitide Decanoate Pre-HemodialysisPanel C: ESRD - Enlicitide Decanoate Post-HemodialysisPanel D: Healthy Controls
Maximum Plasma Concentration (Cmax) of Enlicitide Decanoate9.56 (6.95 to 13.2)5.8 (3.03 to 11.1)8.73 (6.23 to 12.2)9.08 (6.13 to 13.4)9.72 (7.1 to 13.3)
Statistical analysis
  • Panel A: Moderate Renal Impairment (RI) vs Panel D: Healthy Controls · Geometric mean ratio: 0.98 · 90% CI 0.71 to 1.37GMR and 90% confidence interval (CI) were calculated using a linear fixed effects model performed on natural log-transformed values. GMR: Panel A-Moderate Renal Impairment (RI)/Panel D-Healthy controls.
  • Panel B: Severe RI vs Panel D: Healthy Controls · Geometric mean ratio: 0.60 · 90% CI 0.34 to 1.04GMR and 90% confidence interval (CI) were calculated using a linear fixed effects model performed on natural log-transformed values. GMR: Panel B-Severe RI/Panel D-Healthy controls.
  • Panel C: ESRD - Enlicitide Decanoate Pre-Hemodialysis vs Panel D: Healthy Controls · Geometric mean ratio: 0.90 · 90% CI 0.64 to 1.27GMR and 90% confidence interval (CI) were calculated using a linear fixed effects model performed on natural log-transformed values. GMR: Panel C-ESRD Enlicitide Decanoate Pre-Hemodialysis/ Panel D-Healthy Controls.
  • Panel C: ESRD - Enlicitide Decanoate Post-Hemodialysis vs Panel D: Healthy Controls · Geometric mean ratio: 1.18 · 90% CI 0.78 to 1.78GMR and 90% confidence interval (CI) were calculated using a linear fixed effects model performed on natural log-transformed values. GMR: Panel C-ESRD Enlicitide Decanoate Post-Hemodialysis/ Panel D-Healthy Controls.
PrimaryTime to Maximum Plasma Concentration (Tmax) of Enlicitide Decanoate

Tmax was defined as the time required for a study drug to reach maximum concentration in plasma. Blood for plasma samples was collected at pre-specified time points to determine the Tmax of enlicitide decanoate in Panel A, B, C and D participants. Per protocol, Panel C ESRD on HD arm was separated into two arms: Panel C enlicitide decanoate pre-hemodialysis and Panel C enlicitide decanoate post-hemodialysis to report Tmax. Per protocol, mean Tmax was reported.

Time frame:
Predose and 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 120, 168, and 240 hours postdose
Reported as:
Median · hours
Time to Maximum Plasma Concentration (Tmax) of Enlicitide Decanoate
hoursPanel A: Moderate Renal Impairment (RI)Panel B: Severe RIPanel C: ESRD - Enlicitide Decanoate Pre-HemodialysisPanel C: ESRD - Enlicitide Decanoate Post-HemodialysisPanel D: Healthy Controls
Time to Maximum Plasma Concentration (Tmax) of Enlicitide Decanoate16 (1 to 24.25)2.75 (0.5 to 24)18.01 (0.50 to 48)1.00 (0.50 to 24)1.0 (0.5 to 12.03)
PrimaryApparent Terminal Half-life (t1/2) of Enlicitide Decanoate

Half-life (t1/2) was defined as the time required for plasma drug concentration of enclitide decanoate to decrease by 50% from peak. Blood for plasma samples was collected at pre-specified time points to determine the t1/2 of enlicitide decanoate in Panel A, B, C and D participants. Per protocol, Panel C ESRD on HD arm was separated into two arms: Panel C enlicitide decanoate pre-hemodialysis and Panel C enlicitide decanoate post-hemodialysis to report t1/2. Per protocol, mean t1/2 was reported.

Time frame:
Predose and 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 120, 168, and 240 hours postdose
Reported as:
Geometric mean · hours
Apparent Terminal Half-life (t1/2) of Enlicitide Decanoate
hoursPanel A: Moderate Renal Impairment (RI)Panel B: Severe RIPanel C: ESRD - Enlicitide Decanoate Pre-HemodialysisPanel C: ESRD - Enlicitide Decanoate Post-HemodialysisPanel D: Healthy Controls
Apparent Terminal Half-life (t1/2) of Enlicitide Decanoate81.5 ± 70.456.4 ± 32.753.6 ± 36.975.6 ± 62.946 ± 60.8
PrimaryApparent Clearance (CL/F) of Enlicitide Decanoate

CL/F was the apparent total clearance of enlicitide decanoate in plasma over time. Blood for plasma samples was collected at pre-specified timepoints to determine the CL/F of enlicitide decanoate for Panel A, B, C, and D participants. Per protocol, Panel C ESRD on HD arm was separated into two arms: Panel C enlicitide decanoate pre-hemodialysis and Panel C enlicitide decanoate post-hemodialysis to report CL/F. Per protocol, mean CL/F was reported.

Time frame:
Predose and 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 120, 168, and 240 hours postdose
Reported as:
Geometric mean · Liter/hr
Apparent Clearance (CL/F) of Enlicitide Decanoate
Liter/hrPanel A: Moderate Renal Impairment (RI)Panel B: Severe RIPanel C: ESRD - Enlicitide Decanoate Pre-HemodialysisPanel C: ESRD - Enlicitide Decanoate Post-HemodialysisPanel D: Healthy Controls
Apparent Clearance (CL/F) of Enlicitide Decanoate17.6 (12 to 25.9)23.3 (15.9 to 34)15.2 (9.58 to 24)22.6 (16 to 31.9)26.5 (17.2 to 40.8)
Statistical analysis
  • Panel A: Moderate Renal Impairment (RI) vs Panel D: Healthy Controls · Geometric mean ratio: 0.67 · 90% CI 0.43 to 1.02GMR and 90% CI were calculated using a linear fixed effects model performed on natural log-transformed values. GMR: Panel A-Moderate Renal Impairment (RI)/Panel D-Healthy controls
  • Panel B: Severe RI vs Panel D: Healthy Controls · Geometric mean ratio: 0.88 · 90% CI 0.58 to 1.35GMR and 90% confidence interval (CI) were calculated using a linear fixed effects model performed on natural log-transformed values. GMR: Panel B-Severe RI/Panel D-Healthy controls
  • Panel C: ESRD - Enlicitide Decanoate Pre-Hemodialysis vs Panel D: Healthy Controls · Geomtric mean ratio: 0.57 · 90% CI 0.36 to 0.91GMR and 90% CI were calculated using a linear fixed effects model performed on natural log-transformed values. GMR: Panel C-ESRD Enlicitide Decanoate Pre-Hemodialysis/ Panel D-Healthy Controls
  • Panel C: ESRD - Enlicitide Decanoate Post-Hemodialysis vs Panel D: Healthy Controls · Geomtric mean ratio: 0.86 · 90% CI 0.57 to 1.29GMR and 90% CI were calculated using a linear fixed effects model performed on natural log-transformed values. GMR: Panel C-ESRD Enlicitide Decanoate Post-Hemodialysis/ Panel D-Healthy Controls
PrimaryApparent Volume of Distribution (Vz/F) of Enlicitide Decanoate

Vz/F was the apparent volume of distribution of enlicitide decanoate between the plasma and the rest of the body, after dose, assessed as the total volume of enlicitide decanoate that would need to be uniformly distributed to achieve the desired plasma drug concentration. Blood for plasma samples was collected at pre-specified time points to determine the Vz/F of Enlicitide Decanoate in Panel A, B, C, and D participants. Per protocol, Panel C ESRD on HD arm was separated into two arms: Panel C enlicitide decanoate pre-hemodialysis and Panel C enlicitide decanoate post-hemodialysis to report Vz/F. Per protocol, mean Vz/F was reported.

Time frame:
Predose and 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 120, 168, and 240 hours postdose
Reported as:
Geometric mean · Liter
Apparent Volume of Distribution (Vz/F) of Enlicitide Decanoate
LiterPanel A: Moderate Renal Impairment (RI)Panel B: Severe RIPanel C: ESRD - Enlicitide Decanoate Pre-HemodialysisPanel C: ESRD - Enlicitide Decanoate Post-HemodialysisPanel D: Healthy Controls
Apparent Volume of Distribution (Vz/F) of Enlicitide Decanoate2070 (1370 to 3120)1890 (1300 to 2760)1170 (845 to 1620)2470 (1680 to 3620)1760 (1400 to 2210)
Statistical analysis
  • Panel A: Moderate Renal Impairment (RI) vs Panel D: Healthy Controls · Geometric mean ratio: 1.18 · 90% CI 0.83 to 1.67GMR and 90% CI were calculated using a linear fixed effects model performed on natural log-transformed values. GMR: Panel A-Moderate Renal Impairment (RI)/Panel D-Healthy controls
  • Panel B: Severe RI vs Panel D: Healthy Controls · Geometric mean ratio: 1.08 · 90% CI 0.78 to 1.50GMR and 90% confidence interval (CI) were calculated using a linear fixed effects model performed on natural log-transformed values. GMR: Panel B-Severe RI/Panel D-Healthy controls
  • Panel C: ESRD - Enlicitide Decanoate Pre-Hemodialysis vs Panel D: Healthy Controls · Geometric mean ratio: 0.66 · 90% CI 0.50 to 0.89GMR and 90% CI were calculated using a linear fixed effects model performed on natural log-transformed values. GMR: Panel C-ESRD Enlicitide Decanoate Pre-Hemodialysis/ Panel D-Healthy Controls
  • Panel C: ESRD - Enlicitide Decanoate Post-Hemodialysis vs Panel D: Healthy Controls · Geometric mean ratio: 1.40 · 90% CI 1.00 to 1.97GMR and 90% CI for AUC0-inf were calculated using a linear fixed effects model performed on natural log-transformed values. GMR: Panel C-ESRD Enlicitide Decanoate Post-Hemodialysis/ Panel D-Healthy Controls
SecondaryPanel C: Dialysate Clearance (CLd) of Enlicitide Decanoate

CLd was the measure of the amount of enlicitide decanoate cleared from plasma via dialysis. Per protocol, Panel C ESRD on HD arm was separated into two arms: Panel C enlicitide decanoate pre-hemodialysis and Panel C enlicitide decanoate post-hemodialysis. Urine samples were to be collected for Panel C participants to determine mean CLd.

Time frame:
Predose and 0, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, and 48 hours postdose

No measurements were reported for this outcome.

SecondaryPanel C: Dialysate Concentration (Cd) of Enlicitide Decanoate

Cd was the measure of the concentration of enlicitide decanoate in dialysate. Per protocol, Panel C ESRD on HD arm was separated into two arms: Panel C enlicitide decanoate pre-hemodialysis and Panel C enlicitide decanoate post-hemodialysis. Urine samples were to be collected for Panel C participants to determine mean Cd.

Time frame:
Predose and 0, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, and 48 hours postdose

No measurements were reported for this outcome.

SecondaryPanel C: Amount of Enlicitide Decanoate Excreted (AEd) in Dialysate

AEd was the measure of the amount of enlicitide decanoate excreted in the dialysate. Per protocol, Panel C ESRD on HD arm was separated into two arms: Panel C enlicitide decanoate pre-hemodialysis and Panel C enlicitide decanoate post-hemodialysis. Urine samples were to be collected for Panel C participants to determine mean AEd.

Time frame:
Predose and 0, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, and 48 hours postdose

No measurements were reported for this outcome.

SecondaryPanel C: Percentage of Dose (%Dose) of Enlicitide Decanoate Excreted in Dialysate

%Dose was the percentage of the dose of enlicitide decanoate excreted in the dialysate. Per protocol, Panel C ESRD on HD arm was separated into two arms: Panel C enlicitide decanoate pre-hemodialysis and Panel C enlicitide decanoate post-hemodialysis. Urine samples were to be collected for Panel C participants to determine %Dose.

Time frame:
Predose and 0, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, and 48 hours postdose

No measurements were reported for this outcome.

SecondaryAmount of Enlicitide Decanoate Excreted in Urine From 0 to 24 Hours (AE0-24) After Administration of Enlicitide Decanoate

AE0-24 was the measure of the amount of enlicitide decanoate excreted at 0 to 24 hours. Urine samples were to be collected to determine the AE0-24 after administration of enlicitide decanoate for Panels A, B, C, and D. Per protocol, Panel C ESRD on HD arm was separated into two arms: Panel C enlicitide decanoate pre-hemodialysis and Panel C enlicitide decanoate post-hemodialysis to report AE0-24. Per protocol, mean AE0-24 was reported.

Time frame:
Predose and 0, 0.5, 1, 1.5, 2, 4, 8, 12, and 24 hours postdose
Reported as:
Geometric mean · mg
Amount of Enlicitide Decanoate Excreted in Urine From 0 to 24 Hours (AE0-24) After Administration of Enlicitide Decanoate
mgPanel A: Moderate Renal Impairment (RI)Panel B: Severe RIPanel C: ESRD - Enlicitide Decanoate Pre-HemodialysisPanel C: ESRD - Enlicitide Decanoate Post-HemodialysisPanel D: Healthy Controls
Amount of Enlicitide Decanoate Excreted in Urine From 0 to 24 Hours (AE0-24) After Administration of Enlicitide Decanoate0.0213 (0.00846 to 0.0538)0.00592 (0.00211 to 0.0166)——0.0662 (0.0371 to 0.118)
Statistical analysis
  • Panel A: Moderate Renal Impairment (RI) vs Panel D: Healthy Controls · Geometric mean ratio: 0.32 · 90% CI 0.14 to 0.74GMR and 90% CI were calculated using a linear fixed effects model performed on natural log-transformed values. GMR: Panel A-Moderate Renal Impairment (RI)/Panel D-Healthy controls
  • Panel B: Severe RI vs Panel D: Healthy Controls · Geometric mean ratio: 0.09 · 90% CI 0.04 to 0.22GMR and 90% confidence interval (CI) were calculated using a linear fixed effects model performed on natural log-transformed values. GMR: Panel B-Severe RI/Panel D-Healthy controls
SecondaryPercentage of Unchanged Enlicitide Decanoate Excreted in Urine (Fe)

Fe was the measure of the percentage of unchanged enlicitide decanoate excreted in the urine. The percentage of enlicitide decanoate that was excreted unchanged in urine over the 24-hr collection interval (Fe) was calculated as 100 times the ratio of Ae0-24 and dose. Urine samples were to be collected to determine the Fe after administration of enlicitide decanoate for Panels A, B, C, and D. Per protocol, Panel C ESRD on HD arm was separated into two arms: Panel C enlicitide decanoate pre-hemodialysis and Panel C enlicitide decanoate post-hemodialysis to report Fe.

Time frame:
Predose and 0, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, and 48 hours postdose
Reported as:
Geometric mean · Percentage of Enlicitide Decanoate
Percentage of Unchanged Enlicitide Decanoate Excreted in Urine (Fe)
Percentage of Enlicitide DecanoatePanel A: Moderate Renal Impairment (RI)Panel B: Severe RIPanel C: ESRD - Enlicitide Decanoate Pre-HemodialysisPanel C: ESRD - Enlicitide Decanoate Post-HemodialysisPanel D: Healthy Controls
Percentage of Unchanged Enlicitide Decanoate Excreted in Urine (Fe)0.107 (0.0423 to 0.269)0.0296 (0.0105 to 0.0831)——0.331 (0.185 to 0.591)
Statistical analysis
  • Panel A: Moderate Renal Impairment (RI) vs Panel D: Healthy Controls · Geometric mean ratio: 0.32 · 90% CI 0.14 to 0.74GMR and 90% CI were calculated using a linear fixed effects model performed on natural log-transformed values. GMR: Panel A-Moderate Renal Impairment (RI)/Panel D-Healthy controls
  • Panel B: Severe RI vs Panel D: Healthy Controls · Geometric mean ratio: 0.09 · 90% CI 0.04 to 0.22GMR and 90% confidence interval (CI) were calculated using a linear fixed effects model performed on natural log-transformed values. GMR: Panel B-Severe RI/Panel D-Healthy controls
SecondaryRenal Clearance (CLr) of Enlicitide Decanoate

CLr was the measure of how quickly enlicitide decanoate was removed from the plasma by the kidney and excreted in urine. Urine samples were to be collected to determine the CLr after administration of enlicitide decanoate for Panels A, B, C, and D. Per protocol, Panel C ESRD on HD arm was separated into two arms: Panel C enlicitide decanoate pre-hemodialysis and Panel C enlicitide decanoate post-hemodialysis to report CLr. Per protocol, mean CLr was reported.

Time frame:
Predose and 0, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, and 48 hours postdose
Reported as:
Geometric mean · Liter/hr
Renal Clearance (CLr) of Enlicitide Decanoate
Liter/hrPanel A: Moderate Renal Impairment (RI)Panel B: Severe RIPanel C: ESRD - Enlicitide Decanoate Pre-HemodialysisPanel C: ESRD - Enlicitide Decanoate Post-HemodialysisPanel D: Healthy Controls
Renal Clearance (CLr) of Enlicitide Decanoate0.0716 (0.0349 to 0.147)0.0347 (0.0114 to 0.106)——0.243 (0.161 to 0.366)
Statistical analysis
  • Panel A: Moderate Renal Impairment (RI) vs Panel D: Healthy Controls · Geometric mean ratio: 0.29 · 90% CI 0.16 to 0.55GMR and 90% CI were calculated using a linear fixed effects model performed on natural log-transformed values. GMR: Panel A-Moderate Renal Impairment (RI)/Panel D-Healthy controls
  • Panel B: Severe RI vs Panel D: Healthy Controls · Geometric mean ratio: 0.14 · 90% CI 0.06 to 0.36GMR and 90% confidence interval (CI) were calculated using a linear fixed effects model performed on natural log-transformed values. GMR: Panel B-Severe RI/Panel D-Healthy controls
SecondaryNumber of Participants Who Experienced an Adverse Event (AE)

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who experienced an AE were reported.

Time frame:
Up to approximately 30 days
Reported as:
Count of participants · Participants
Number of Participants Who Experienced an Adverse Event (AE)
ParticipantsPanel A: Moderate Renal Impairment (RI)Panel B: Severe RIPanel C: End-Stage Renal Disease (ESRD) on Hemodialysis (HD)Panel D: Healthy Controls
Number of Participants Who Experienced an Adverse Event (AE)2210
SecondaryPanels A, B, and D: Number of Participants Who Discontinued From the Study Due to an AE

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of Panel A, B, and D participants who discontinued study treatment due to an AE were reported.

Time frame:
Up to approximately 30 days
Reported as:
Count of participants · Participants
Panels A, B, and D: Number of Participants Who Discontinued From the Study Due to an AE
ParticipantsPanel A: Moderate Renal Impairment (RI)Panel B: Severe RIPanel D: Healthy Controls
Panels A, B, and D: Number of Participants Who Discontinued From the Study Due to an AE000
SecondaryPanel C: Number of Participants Who Discontinued From the Study Treatment Due to an AE

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of Panel C participants who discontinued study treatment due to an AE were reported.

Time frame:
Up to approximately 30 days
Reported as:
Count of participants · Participants
Panel C: Number of Participants Who Discontinued From the Study Treatment Due to an AE
ParticipantsPanel C: End-Stage Renal Disease (ESRD) on Hemodialysis (HD)
Panel C: Number of Participants Who Discontinued From the Study Treatment Due to an AE0

Adverse events

Collected over Up to approximately 30 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Panel A: Moderate Renal Impairment (RI)0/8 (0%)0/8 (0%)2/8 (25%)
Panel B: Severe RI0/8 (0%)0/8 (0%)2/8 (25%)
Panel C: End-Stage Renal Disease (ESRD) on Hemodialysis (HD)0/9 (0%)1/9 (11.1%)0/9 (0%)
Panel D: Healthy Controls0/8 (0%)0/8 (0%)0/8 (0%)
Most frequent serious events
Most frequent serious events
EventPanel A: Moderate Renal Impairment (RI)Panel B: Severe RIPanel C: End-Stage Renal Disease (ESRD) on Hemodialysis (HD)Panel D: Healthy Controls
HypervolaemiaMetabolism and nutrition disorders0/80/81/90/8
Most frequent other events
Most frequent other events
EventPanel A: Moderate Renal Impairment (RI)Panel B: Severe RIPanel C: End-Stage Renal Disease (ESRD) on Hemodialysis (HD)Panel D: Healthy Controls
Dry mouthGastrointestinal disorders1/80/80/90/8
Animal biteInjury, poisoning and procedural complications0/81/80/90/8
HypertensionVascular disorders1/80/80/90/8
Orthostatic hypotensionVascular disorders0/81/80/90/8

Baseline characteristics

All allocated participants

Age, Continuous
Age, Continuous(Years)Panel A: Moderate Renal Impairment (RI)Panel B: Severe RIPanel C: End-Stage Renal Disease (ESRD) on Hemodialysis (HD)Panel D: Healthy ControlsTotal
Mean67 ± 9.666.8 ± 12.160.1 ± 9.662.8 ± 464 ± 9.3
Sex: Female, Male
Sex: Female, Male(Participants)Panel A: Moderate Renal Impairment (RI)Panel B: Severe RIPanel C: End-Stage Renal Disease (ESRD) on Hemodialysis (HD)Panel D: Healthy ControlsTotal
Female15129
Male738624
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Panel A: Moderate Renal Impairment (RI)Panel B: Severe RIPanel C: End-Stage Renal Disease (ESRD) on Hemodialysis (HD)Panel D: Healthy ControlsTotal
Hispanic or Latino622515
Not Hispanic or Latino267318
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Panel A: Moderate Renal Impairment (RI)Panel B: Severe RIPanel C: End-Stage Renal Disease (ESRD) on Hemodialysis (HD)Panel D: Healthy ControlsTotal
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American157316
White732517
More than one race00000
Unknown or Not Reported00000
08

Study locations

5 sites
  • Velocity Clinical Research, Hallandale Beach ( Site 0003)
    Hallandale, Florida 33009, United States
  • Clinical Pharmacology of Miami ( Site 0005)
    Miami, Florida 33014-3616, United States
  • Advanced Pharma CR, LLC ( Site 0001)
    Miami, Florida 33147, United States
  • Orlando Clinical Research Center ( Site 0004)
    Orlando, Florida 32809, United States
  • Genesis Clinical Research, LLC ( Site 0002)
    Tampa, Florida 33603, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2023 to primary completion in Jan 2024, 5 months.

Results were first posted in Feb 2025, 1 year after primary completion.

Of 41 industry-sponsored phase 1 interventional studies under Hypercholesterolemia, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 5 months is below that.

Counting every sponsor, half of 46 studies reached it within 7 months; a quarter within 2 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2023
First posted
Jul 6, 2023
StartActual
Jul 20, 2023
Primary completionActual
Jan 19, 2024
CompletionActual
Jan 19, 2024
Results first posted
Feb 17, 2025
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Posted results revised
revised Sep 30, 2026
Sites
1 site added, 1 site removed
Show site
  • Velocity Clinical Research, Hallandale Beach ( Site 0003) · Hallandale, United States
Show 1 removed
  • Velocity Clinical Research, Hallandale Beach ( Site 0003) · Hallandale Beach, United States
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Posted results revised
    1 site added, 1 site removed
    Show site
    • Velocity Clinical Research, Hallandale Beach ( Site 0003) · Hallandale, United States
    Show 1 removed
    • Velocity Clinical Research, Hallandale Beach ( Site 0003) · Hallandale Beach, United States
    + 3 other changes: verification date, registry notes and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05934292
Responsible party
Sponsor
First posted
Jul 6, 2023
Start date
Jul 20, 2023
Primary completion
Jan 19, 2024
Completion
Jan 19, 2024
Results posted
Feb 17, 2025
Last update
Sep 30, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MK-0616

Start the discussion